TABLE 2.
Study | Pitavastatin (n = 18) | Atorvastatin (n = 18) | Rosuvastatin (n = 29) | Pravastatin (n = 18) | Simvastatin (n = 20) | Fluvastatin (n = 19) | Total (n = 122) |
---|---|---|---|---|---|---|---|
Any adverse event | 4 [3] | 15 [11] | 18 [14] | 7 [5] | 16 [10] | 17 [10] | 77 [53] |
Pemafibrate alone | 2 [1] | 6 [4] | 3 [3] | 2 [2] | 2 [2] | 3 [2] | 18 [14] |
Statin alone | 1 [1] | 6 [6] | 6 [6] | 2 [2] | 6 [4] | 7 [6] | 28 [25] |
Combination | 1 [1] | 3 [3] | 9 [7] | 3 [3] | 8 [6] | 7 [6] | 31 [26] |
Adverse event leading to discontinuation | 0 | 0 | 3 [3] | 0 | 0 | 0 | 3 [3] |
Pemafibrate alone | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Statin alone | 0 | 0 | 1 [1] a | 0 | 0 | 0 | 1 [1] |
Combination | 0 | 0 | 2 [2] b , c | 0 | 0 | 0 | 2 [2] |
Death or serious adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Severe adverse event | 0 | 0 | 1 [1] b | 0 | 0 | 0 | 1 [1] |
Moderate adverse event | 1 [1] d | 0 | 2 [2] a , e | 0 | 0 | 0 | 3 [3] |
Mild adverse event | 1 [1] | 5 [4] | 14 [11] | 1 [1] | 7 [5] | 9 [7] | 37 [29] |
Laboratory test abnormal | 2 [2] | 10 [9] | 1 [1] c | 6 [4] | 9 [6] | 8 [5] | 36 [27] |
Adverse event for which a causal relationship with study drugs could not be ruled out | 1 [1] | 8 [6] | 0 | 3 [2] | 10 [7] | 12 [9] | 34 [25] |
Data are presented as the number of events [the number of participants who had at least one event].
Musculoskeletal chest pain.
Sciatica.
Blood creatine phosphokinase increased.
Gastroenteritis.
Viral upper respiratory tract infection.